BioCryst faces tight competition in H1N1 flu drug market
BioCryst Pharmaceuticals is facing tough competition from other makers of H1N1 flu drugs because of the high price of its intravenous treatment candidate peramivir. The U.S. government ordered 10,000 treatment courses of peramivir on an emergency basis, but it also bought intravenous formulations of Roche Holding's Tamiflu and GlaxoSmithKline's Relenza, which are cheaper than peramivir's $2,250-per-patient price tag.
NYTimes.com
| 11/5
This story published in FMI Pharmacy dailyLead on 11/06/2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|